



CSL Research Acceleration Initiative

Applications close 24th February 2026

WHY COLLABORATE WITH CSL?



Funding of up to \$400,000 USD over 2 years



Access global capabilities and expertise
CSL scientific champion assigned to provide industry guidance and help you leverage our global capabilities



Publish with CSL
270+ publications with our collaborators since 2020



Accelerate Translation of your research into new therapies

CSL is a leading global biotech company delivering innovative therapies to help people with life-threatening conditions live full lives.

The CSL **Research Acceleration Initiative** supports early-stage biotechs and research organizations to fast-track the discovery of groundbreaking biotherapies.

Successful applicants can receive up to **\$400,000 USD in non-dilutive funding** over 2 years to advance their innovative programs.

Interested researchers are invited to:

- **Attend an information webinar (choose one of two sessions)**

Wednesday, 28 January 1:00PM AEDT – [Click to join](#)

Thursday, 5 February 2:00PM AEDT – [Click to join](#)

- **Submit enquiries, expressions of interest and requests for application instructions to:**

Name:

Email:

- **Submit** a non-confidential, 500-word abstract via the CSL online application portal by **24th February 2026**.

The 2026 Research Acceleration Initiative will focus on research proposals that align with a CSL **Therapeutic Area**. Please see over page for specific **Focus Areas**.

Therapeutic Areas



Immunoglobulins



Hematology



Cardio-Renal



Transplant & Immunology

CSL Research Acceleration Initiative

Focus Areas



CSL is seeking applications that align with a CSL Therapeutic Area in the following Focus Areas

<div>Transplant & Immunology</div> <div>Novel first in class targets and drug concepts to treat immune-mediated diseases e.g.</div> <div><ul style="list-style-type: none">Strategies for targeting pathogenic T cell subsetsStrategies for targeting disease-driving chemokine receptorsMulti-specific approaches that enable multiple cell types/ pathways to be targeted to treat complex immune-mediated diseasesStrategies for targeting stromal cells, senescence or inflammaging</div> <div>Indication focus</div> <div><ul style="list-style-type: none">Chronic immune mediated rheumatologic and dermatologic diseasesRare neuro-immune disorders</div>	<div>Cardiovascular & Renal</div> <div>Genetic rare renal diseases</div> <div><p>Novel targets or therapeutic candidates for polycystic kidney disease autosomal dominant tubulointerstitial kidney disease and Alport syndrome</p></div> <div>Autoimmune-mediated rare renal diseases</div> <div><p>Novel targets or therapeutic candidates for autoimmune-mediated rare glomerular diseases and ANCA-associated vasculitis</p></div> <div>Rare cardiovascular diseases</div> <div><p>Novel targets or therapeutic candidates for inflammatory, autoimmune or genetic cardiomyopathies</p></div> <div><p>Novel targets or therapeutic candidates for immune checkpoint inhibitor-induced myocarditis</p></div>	<div>Hematology</div> <div>Acute hemorrhage control and Patient Blood Management (PBM)</div> <div><ul style="list-style-type: none">Pro-hemostatic therapies for anti-platelet agent-associated hemorrhage and intracerebral hemorrhageTreatments for targeting and preventing hyperfibrinolysis- and vascular malformations-associated bleeding</div> <div>Transformative therapies for Hemophilia A</div> <div><ul style="list-style-type: none">Next generation non-AAV-based gene therapyOral protein or nucleic acid-based treatments</div> <div>Iron metabolism</div> <div><ul style="list-style-type: none">Novel treatments for iron deficiency and anemiaNovel formulation approaches: oral & intramuscular iron supplementationNovel therapies to treat iron overload conditionsDisease modifying therapies for myeloproliferative neoplasms including polycythemia vera , essential thrombocythemia, myelofibrosis and myelodysplastic syndrome</div> <div>Acute thrombotic conditions</div> <div><p>Novel therapies applicable to a broad spectrum of acute thrombotic diseases including microangiopathies (TMAs; pan-treatment)</p></div>
<div>Immunoglobulins</div> <div>Patient Experience</div> <div><ul style="list-style-type: none">High concentration/low volume formulation technologiesImprove ease of administration and decrease administration time for plasma-derived productsTechnologies that enable novel routes of administration for plasma-derived products</div> <div>Novel Therapies for</div> <div><ul style="list-style-type: none">Primary and Secondary Immunodeficiency DisordersAlpha 1 Antitrypsin Deficiency</div> <div>Optimization of human-derived Ig products</div> <div><ul style="list-style-type: none">Technologies that can optimize, supplement or replace human-derived products</div>		
<div>Oral Delivery</div> <div>Technologies enabling systemic oral delivery of biologics (e.g. antibodies and other large proteins)</div>		